[
  {
    "objectID": "FUO.html#fever-of-unknown-origin-fuo",
    "href": "FUO.html#fever-of-unknown-origin-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Fever of unknown origin (FUO)",
    "text": "Fever of unknown origin (FUO)\n\n\nRussell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  13 March 2023"
  },
  {
    "objectID": "FUO.html#objectives",
    "href": "FUO.html#objectives",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Objectives",
    "text": "Objectives"
  },
  {
    "objectID": "FUO.html#the-history-of-fever",
    "href": "FUO.html#the-history-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "The history of fever",
    "text": "The history of fever\n\n\n\n10th Century BCE Persian Physician Akhawayni defined a system for fever curves in Hidāyat al-Muta’allimīn fī al-Tibb (The Student’s Handbook of Medicine)\nHippocratic physicians proposed that body temperature, and physiologic harmony in general, involved a delicate balance among four corporal humors—blood, phlegm, black bile, and yellow bile.\n\nFever was due to excess of yellow bile (many infections caused jaundice)\n\nGalen: many types of fever developed from putrification of humors.\nMiddle ages: demonic possession\n18th century (Harvey’s discovery of circulation)- friction of blood flow through body causing fermentation and putrification in intestines\nClaude Bernard in the 19th century- metabolic processes in the body"
  },
  {
    "objectID": "FUO.html#febris--roman-goddess-of-fever",
    "href": "FUO.html#febris--roman-goddess-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Febris- Roman Goddess of Fever",
    "text": "Febris- Roman Goddess of Fever\n\n\n\nThe legend of Febris was said to center around the haunting marshes of Camagna in Southern Italy where like clockwork every year, the people would become deathly ill with a mysterious disease. She was so feared by the Romans that the suffering population had created a cult to Febris. They went so far as to wear protective amulets and build her temples in order to worship her to win her favour."
  },
  {
    "objectID": "FUO.html#galileo-and-the-room-thermometer-in-padova",
    "href": "FUO.html#galileo-and-the-room-thermometer-in-padova",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Galileo and the room thermometer in Padova",
    "text": "Galileo and the room thermometer in Padova"
  },
  {
    "objectID": "FUO.html#fever-in-modern-medicine",
    "href": "FUO.html#fever-in-modern-medicine",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Fever in modern medicine",
    "text": "Fever in modern medicine\n\nWunderlich’s pioneering studies of thermometry-normal 37°C\nSince the 19th century, humans have become gradually colder-0.05° to 0.5°C per decade\nCurrent normal range is 36.3 to 36.5°C\n\n\n\n(Mackowiak and Worden, 1994)"
  },
  {
    "objectID": "FUO.html#thermal-homeostasis",
    "href": "FUO.html#thermal-homeostasis",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Thermal homeostasis",
    "text": "Thermal homeostasis\n\n\n\n\n\n\n\n(Sajadi, Mohammad M. and Mackowiak, Philip A., n.d.)"
  },
  {
    "objectID": "FUO.html#infection-associated-fever",
    "href": "FUO.html#infection-associated-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Infection-associated fever",
    "text": "Infection-associated fever\n\n\n\n\n\n\n\n(Sajadi, Mohammad M. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#sequelae-of-fever",
    "href": "FUO.html#sequelae-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Sequelae of fever",
    "text": "Sequelae of fever\n\n\nPhylogenetic conservation of fever over the millennia suggests fever is beneficial\nMost pathogenic bacteria are mesophiles (35°C ideal for growth)\nFever generates hepatic iron-sequestering compounds the bind free iron necessary for microbial replication"
  },
  {
    "objectID": "FUO.html#acute-phase-proteins",
    "href": "FUO.html#acute-phase-proteins",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Acute phase proteins",
    "text": "Acute phase proteins\n\n\n(Gabay and Kushner, 1999)"
  },
  {
    "objectID": "FUO.html#acute-phase-phenomena",
    "href": "FUO.html#acute-phase-phenomena",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Acute phase phenomena",
    "text": "Acute phase phenomena\n\n\n(Gabay and Kushner, 1999)"
  },
  {
    "objectID": "FUO.html#epidemiology-of-fuo--definitions",
    "href": "FUO.html#epidemiology-of-fuo--definitions",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Epidemiology of FUO- Definitions",
    "text": "Epidemiology of FUO- Definitions\n\n\n\n\n\n\n\n(Haidar and Singh, 2022)"
  },
  {
    "objectID": "FUO.html#classic-fuo",
    "href": "FUO.html#classic-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO",
    "text": "Classic FUO\n\n\nDefinition:\n\nTemperature of > 38.3°C > 3 weeks\nFever >2 separate outpatient visits with diagnostic investigations or\nFever >2 visits in hospital of 3 days with diagnostic investigations\n\nHowever, these definitions are largely subjective\n\n\nLeading causes:\n\nCancer (age dependent)\nInfections (geography dependent)\nInflammatory conditions (age dependent)\nUndiagnosed habitual hyperthermia"
  },
  {
    "objectID": "FUO.html#frequency-of-the-5-main-etiologic-categories-of-fuo",
    "href": "FUO.html#frequency-of-the-5-main-etiologic-categories-of-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Frequency of the 5 main etiologic categories of FUO",
    "text": "Frequency of the 5 main etiologic categories of FUO\nInfectious causes decrease in patients above age 65 years\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#classic-fuo--infectious-etiology",
    "href": "FUO.html#classic-fuo--infectious-etiology",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO- Infectious Etiology",
    "text": "Classic FUO- Infectious Etiology\n\nOccult abscess\nEndocarditis\nTuberculosis\nComplicated urinary tract infections"
  },
  {
    "objectID": "FUO.html#classic-fuo-work-up",
    "href": "FUO.html#classic-fuo-work-up",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO work-up",
    "text": "Classic FUO work-up\n\n\nMedical history emphasis:\n\nTravel\nContacts\nAnimal and insect exposure\nMedications\nImmunizations\nFamily history\nCardiac valve disorder\n\nExamination emphasis\n\nFundi, oropharynx, temporal artery, abdomen, lymph nodes, spleen, joints, skin, nails, genitalia, rectum or prostate, lower limb deep veins\n\nInvestigation emphasis:\n\nImaging, biopsies, sedimentation rate, skin tests"
  },
  {
    "objectID": "FUO.html#rare-and-miscellaneous-causes-of-fever",
    "href": "FUO.html#rare-and-miscellaneous-causes-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Rare and miscellaneous causes of fever",
    "text": "Rare and miscellaneous causes of fever"
  },
  {
    "objectID": "FUO.html#distinctive-fever-patterns",
    "href": "FUO.html#distinctive-fever-patterns",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Distinctive fever patterns",
    "text": "Distinctive fever patterns\n\nA. Maleria; B. Typhoid fever with relative bradycardia; C. Hodgkin’s disease (Pel-Ebstein pattern);  D. Borreliosis (relapsing fever pattern)\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#classic-fuo-in-infants-and-children",
    "href": "FUO.html#classic-fuo-in-infants-and-children",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO in infants and children",
    "text": "Classic FUO in infants and children\n\n\nRespiratory tract infections\nOther infections: UTIs, brucellosis, tuberculosis, bartonellosis\nKawasaki disease (age < 5 years)\nInflammatory bowel diseases\nStill’s disease (juvenile rheumatoid arthritis)\n\nHowever, connective tissue diseases and cancers are generally rare in children\n\nJoint involvement is an important sign of a potentially serious disorder- e.g., connective tissue disease, endocarditis, leukemia"
  },
  {
    "objectID": "FUO.html#classic-fuo-in-elderly-patients",
    "href": "FUO.html#classic-fuo-in-elderly-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO in elderly patients",
    "text": "Classic FUO in elderly patients\n\n\nIn developed countries: connective tissue diseases > infections\n\nTemporal arteritis\nPolymyalgia rheumatic syndromes\n\nDiagnoses are frequently missed because symptoms are subacute and non-specific\nInfections\n\nintraabdominal abscess\nComplicated UTIs\nTuberculosis\nEndocarditis"
  },
  {
    "objectID": "FUO.html#returning-travellers",
    "href": "FUO.html#returning-travellers",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Returning travellers",
    "text": "Returning travellers\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#nosocomial-health-care-associated-fuo",
    "href": "FUO.html#nosocomial-health-care-associated-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Nosocomial (Health-Care Associated) FUO",
    "text": "Nosocomial (Health-Care Associated) FUO\n\n\nLeading causes:\n\nDrug fever\nPost-operative complications (e.g., occult abscess)\nDecubitus ulcers\nSeptic thrombophlebitis\nRecurrent pulmonary emboli\nMyocardial infarction\nCancer\nBlood transfusion\nClostridium difficile colitis"
  },
  {
    "objectID": "FUO.html#fever-in-post-operative-patients",
    "href": "FUO.html#fever-in-post-operative-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Fever in post-operative patients",
    "text": "Fever in post-operative patients\n\n\nAlthough more than 1/3 of patients may manifest fever in first 5 days surgery, < 10% of febrile patients have an identified source\nPhysiological response to surgically-induced tissue injury with release of pyrogenic cytokines and interleukins rather than result of infection"
  },
  {
    "objectID": "FUO.html#fuo-in-icu-patients",
    "href": "FUO.html#fuo-in-icu-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "FUO in ICU patients",
    "text": "FUO in ICU patients\n\n\nEarly fevers are common, often non-infectious, associated with good prognosis\nProlonged fever- poorer prognosis\nSinusitis as a complication of mechanical ventilation, supine position, feeding tubes\nOther causes are similar to nosocomial infections\n\nAbscess\nDrug fever\npostoperative complications\nSeptic thrombophlebitis\nRecurrent pulmonary emboli\nMyocardial infarction"
  },
  {
    "objectID": "FUO.html#fuo-in-stroke-patients",
    "href": "FUO.html#fuo-in-stroke-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "FUO in stroke patients",
    "text": "FUO in stroke patients\n\n\nNon-infective fevers are commonly seen in patients with intracranial mass effects and occur earlier after stroke than infection\nUTI are common related to urinary catheterization"
  },
  {
    "objectID": "FUO.html#fuo-in-neutropenic-patients",
    "href": "FUO.html#fuo-in-neutropenic-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "FUO in neutropenic patients",
    "text": "FUO in neutropenic patients\n\n\n\nANC= Total WBC x (% Segs + % Bands)\nANC of < 500 cells/mm3 or an ANC that is expected to decrease to < 500 cells/mm3 during the next 48 h.\n\nThe term “profound” is sometimes used to describe neutropenia in which the ANC is < 100 cells/mm3\n\nFever occurs frequently during chemotherapy-induced neutropenia:\n\n10%–50% of patients with solid tumors\n80% of those with hematologic malignancies will develop fever during >1 chemotherapy cycle associated with neutropenia\n\nMost patients will have no infectious etiology documented.\nSigns of inflammation are notoriously absent other than fever"
  },
  {
    "objectID": "FUO.html#clinical-manifestations-of-infection-related-to-absolute-neutrophil-count-anc",
    "href": "FUO.html#clinical-manifestations-of-infection-related-to-absolute-neutrophil-count-anc",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Clinical manifestations of infection related to absolute neutrophil count (ANC)",
    "text": "Clinical manifestations of infection related to absolute neutrophil count (ANC)\n\n\n\n\n\n\n\n\n\n\nSigns and symptoms\nInfection\n% of patients with ANC< 100\n% of patients with ANC>1000\n\n\n\n\nFever\nOverall\n98\n76\n\n\nBacteremia\nOverall\n43\n13\n\n\nFluctuance\nAnorectal\n8\n67\n\n\nExudate\nSkin\n5\n92\n\n\nPurulent sputum\nPneumonia\n8\n84\n\n\nPyuria\nUTI\n11\n97\n\n\n\n\n\n(Sickles et al., 1975)"
  },
  {
    "objectID": "FUO.html#possible-causes-of-fever-in-neutropenic-patients-not-responding-to-broad-spectrum-antibiotics",
    "href": "FUO.html#possible-causes-of-fever-in-neutropenic-patients-not-responding-to-broad-spectrum-antibiotics",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Possible causes of fever in neutropenic patients not responding to broad-spectrum antibiotics",
    "text": "Possible causes of fever in neutropenic patients not responding to broad-spectrum antibiotics\n\n\n(Corey and Boeckh, 2002)"
  },
  {
    "objectID": "FUO.html#naproxen-nsiad-fever-suppression-test",
    "href": "FUO.html#naproxen-nsiad-fever-suppression-test",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Naproxen (NSIAD) fever suppression test",
    "text": "Naproxen (NSIAD) fever suppression test\n\nA trial of naproxen may differentiate neoplastic from non-neoplastic fever\n\nTemperature >37.8°C at least once a day;\nDuration of fever >2 weeks;\nLack of evidence of infection (eg physical examination, laboratory examinations, and imaging studies);\nAbsence of allergic mechanisms (eg, drug allergy, transfusion reaction, and radiation or chemotherapeutic drug reaction);\nLack of response of fever to an empiric, adequate antibiotic therapy for at least 7 days;\nPrompt complete lysis by the naproxen test with sustained normal temperature while receiving naproxen."
  },
  {
    "objectID": "FUO.html#cell-mediated-immunity-1",
    "href": "FUO.html#cell-mediated-immunity-1",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Cell-mediated immunity-1",
    "text": "Cell-mediated immunity-1\n\n\n\n(Playfair, J. and Bancroft, G., 2013)"
  },
  {
    "objectID": "FUO.html#cell-mediated-immunity-2",
    "href": "FUO.html#cell-mediated-immunity-2",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Cell-mediated immunity-2",
    "text": "Cell-mediated immunity-2\n\n\n(Playfair, J. and Bancroft, G., 2013)"
  },
  {
    "objectID": "FUO.html#cell-mediated-immunity-drug-allergy",
    "href": "FUO.html#cell-mediated-immunity-drug-allergy",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Cell-mediated immunity-Drug allergy",
    "text": "Cell-mediated immunity-Drug allergy\n\n\n(Playfair, J. and Bancroft, G., 2013)"
  },
  {
    "objectID": "FUO.html#infections-in-immunocompromised-hosts",
    "href": "FUO.html#infections-in-immunocompromised-hosts",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Infections in immunocompromised hosts",
    "text": "Infections in immunocompromised hosts"
  },
  {
    "objectID": "FUO.html#hiv-related-fuo",
    "href": "FUO.html#hiv-related-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "HIV-related FUO",
    "text": "HIV-related FUO\n\nPrimary phase of infection characterized by mononucleosis-like illness where fever is common, may be undiagnosed if it precedes seroconversion\nIn later phases of untreated HIV, episodes of fever become common and often signify a superimposed illness- e.g., opportunistic infections that manifest in atypical fashion\nOnce highly-active antiretroviral therapy (HAART) is started and HIC viral load is effectively suppressed, the frequency of FUO falls markedly"
  },
  {
    "objectID": "FUO.html#etiology-of-fever-in-hiv-associated-fuo-n70",
    "href": "FUO.html#etiology-of-fever-in-hiv-associated-fuo-n70",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Etiology of fever in HIV-Associated FUO (n=70)",
    "text": "Etiology of fever in HIV-Associated FUO (n=70)\n\n\n\n\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#diagnosis-of-fuo",
    "href": "FUO.html#diagnosis-of-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Diagnosis of FUO",
    "text": "Diagnosis of FUO"
  },
  {
    "objectID": "FUO.html#general-diagnostic-evaluation-of-fuo",
    "href": "FUO.html#general-diagnostic-evaluation-of-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "General diagnostic evaluation of FUO",
    "text": "General diagnostic evaluation of FUO\n\n\n\n\n\n\nComprehensive history\n\n\n\n\nRepeated physical exams\n\n\nComplete blood count\n\n\nRoutine blood chemistry\n\n\nUrinalysis including microscopic examination\n\n\nChest radiograph\n\n\nErythrocyte sedimentation rate\n\n\nAntinuclear antibodies\n\n\nRheumatoid factor\n\n\nBlood cultures- three separate specimens in the absence of antimicrobial therapy\n\n\nCMV IgM antibodies or viral detection in blood\n\n\nHeterophil antibody test in children and young adults\n\n\nTuberculin skin test\n\n\nComputed tomography of abdomen, pelvis and other sites\n\n\nMRI/Radionucleotide scans\n\n\nHIV antibodies or viral detection assay\n\n\nFurther evaluation of any abnormality detected by above tests\n\n\nVarious duplex imaging of lower limbs\n\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#patient-history",
    "href": "FUO.html#patient-history",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Patient history",
    "text": "Patient history\n\n\n\nHelps guide choice of initial laboratory investigations\nParticular attention should be give to:\n\nrecent travel\nexposure to pets and other animals\nwork environment\nrecent contact with people with similar symptoms\nfamily history (e.g., familial Mediterranean fever)\n\nPrior history of FUO\nPreviously diagnosed conditions\n\nlymphoma\nrheumatic fever\nintraabdominal disorders\n\nComplete list of medications"
  },
  {
    "objectID": "FUO.html#verification-of-fever-and-fever-pattern",
    "href": "FUO.html#verification-of-fever-and-fever-pattern",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Verification of fever and fever pattern",
    "text": "Verification of fever and fever pattern\n\n\nSeems obvious, but often overlooked\nIn some series, up to 30% where determined not to have fever\nFever patterns- arcane terminology:\n\nremittent, intermittent, hectic, quotidian, sustained, quartan, saddleback fevers\n\nFever patterns are affected by:\n\nHydration, ambient temperature\nAccuracy of temperature measurements\nUse of antipyretics, corticosteroids\nBlood transfusions, other medical interventions etc."
  },
  {
    "objectID": "FUO.html#continuous-sustained-fever",
    "href": "FUO.html#continuous-sustained-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Continuous sustained fever",
    "text": "Continuous sustained fever\n\n\nContinuous (sustained) fever with slight remission not exceed 2°C\n\nLobar and Gram negative pneumonia\nRickettsiosis\nTyphoid fever\nCNS disorders\nTularemia\nFalciparum (malignant tertian) malaria :::"
  },
  {
    "objectID": "FUO.html#intermittent-fever",
    "href": "FUO.html#intermittent-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Intermittent fever",
    "text": "Intermittent fever\n\n\nIntermittent (septic, quotidian, “picket fence”) fever with wide fluctuations, usually norma or low in the morning and peaking between 4:00 and 8:00 PM\n\nLocalized pyogenic infections and bacterial endocarditis with chills and leukocytosis\nMalaria (often with leukopenia) may present with daily (quotidian) daily spike or (tertian) spike every 3rd day, or (quartan) spike every 4th day.\nDouble quotidian patter (two daily spikes) aen with salmonellosis, miliary tuberculosis, double malarial infections (more than one species), gonococcal and meningococcal endocarditis\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#saddle-back-biphasic",
    "href": "FUO.html#saddle-back-biphasic",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Saddle-back (biphasic)",
    "text": "Saddle-back (biphasic)\n\n\nSeveral days of fever, distinct reductio in fever for ~ 1 day, and then several days of higher fever\n\nDengue and yellow fever\nColorado tick fever\nRift valley Fever\nInfluenzae and other viral infections\n\n\n\n\n\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#intermittent-hectic-charcots-fever",
    "href": "FUO.html#intermittent-hectic-charcots-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Intermittent hectic (Charcot’s) fever",
    "text": "Intermittent hectic (Charcot’s) fever\n\n\nSporadic episodes of fever, periods of noram temperature with recurrence\n\nFrequently seen in cholangitis associated with cholelithiasis, jaundice, leukocytosis and toxic signs\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#pel-ebstein-fever",
    "href": "FUO.html#pel-ebstein-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Pel-Ebstein fever",
    "text": "Pel-Ebstein fever\n\n\nWeekly or longer periods of fever and equally long afebrile periods, with repetition of the cycle\n\nHodgkin’s disease\nBrucellosis due to Brucella melitensis\nOccasionally tuberculosiso\n\n\n\n\n\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#typus-inversus",
    "href": "FUO.html#typus-inversus",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Typus Inversus",
    "text": "Typus Inversus\n\n\nReversal of diurnal pattern, with highest temperatures in the early morning hours rather than during the late afternoon or evening\n\nMiliary TB\nSalmonelloses\nHepatic abscess\nBacterial endocarditis\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#jarisch-herxheimer-reaction",
    "href": "FUO.html#jarisch-herxheimer-reaction",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Jarisch-Herxheimer reaction",
    "text": "Jarisch-Herxheimer reaction\n\n\n\nSharply increased elevation of temperature with shivers and chills occurs within several hours after starting penicillin therapy\n\nPrimary or secondary syphilis Leptospirosis or tick-borne relapsing fever\nTetracycline or chloramphenicol therapy for acute brucellosis\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#physical-examination",
    "href": "FUO.html#physical-examination",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Physical examination",
    "text": "Physical examination\n\nSome signs are subtle and may require repeated exams to be appreciated\nVigorous search for lymphadenopathy (consideration for biopsy)\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#laboratory-investigations",
    "href": "FUO.html#laboratory-investigations",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Laboratory investigations",
    "text": "Laboratory investigations\n\n“The cause is more often a common disease presenting in an atypical fashion than a rare disease presenting in a typical fashion.\n\nMultiple diagnostic algorithms in the literature\nMust be selectively applied or will result in excessive unfocused diagnositc testing\n\nFalse positives\nMisguided treatment plans\n\nHistory and physical exam (most important) should guide the choice and sequence of tests"
  },
  {
    "objectID": "FUO.html#examples-of-potential-diagnostic-clues",
    "href": "FUO.html#examples-of-potential-diagnostic-clues",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Examples of potential diagnostic clues",
    "text": "Examples of potential diagnostic clues\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#other-diagnostic-considerations-bone-marrow-biopsy",
    "href": "FUO.html#other-diagnostic-considerations-bone-marrow-biopsy",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Other diagnostic considerations:  bone marrow biopsy",
    "text": "Other diagnostic considerations:  bone marrow biopsy\n\n\nGranulomatous infections (e.g., tuberculosis, histoplasmosis, sarcoidosis)\nPatients with abnormal complete blood counts (CBC)"
  },
  {
    "objectID": "FUO.html#imaging-studies",
    "href": "FUO.html#imaging-studies",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Imaging studies",
    "text": "Imaging studies\n\n\nGenerally low diagnostic yield without localizing symptoms\n\nCT of abdomen, chest\nUltrasound of gallbladder and hepatobiliary systems\nCT pulmonary angiograms for pulmonary embolus\nMRI for CNS, abdomen spleen and lymph nodes Aortic arch and proximal cervical arteries (vasculitis)\nGallium-67 (67Ga) scanning (becoming less common)"
  },
  {
    "objectID": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet",
    "href": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)",
    "text": "18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)\n\n\n\n(de Kleijn et al., 1997; Wright et al., 2021)"
  },
  {
    "objectID": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet-1",
    "href": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet-1",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "F-fluorodeoxyglucose (FDG) positron emission tomography (PET)",
    "text": "F-fluorodeoxyglucose (FDG) positron emission tomography (PET)\n\n\n\n(Kouijzer et al., 2018)"
  },
  {
    "objectID": "FUO.html#invasive-diagnostic-procedures",
    "href": "FUO.html#invasive-diagnostic-procedures",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Invasive diagnostic procedures",
    "text": "Invasive diagnostic procedures\n \n\nHistopathological examination of tissues obtained by excisional biopsy , needle biopsy or laparotomy can provide definitive diagnosis in some cases\nMajority of FUO patients will undergo at least one procedure"
  },
  {
    "objectID": "FUO.html#treatment",
    "href": "FUO.html#treatment",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Treatment",
    "text": "Treatment\n\n\nA fundamental principle in classic FUO is that therapy should be withheld until the cause of fever is determined\n\nNon-specific treatment rarely “cures” FUO\nEmpiric treatment may delay the clinical diagnosis\n\nClinical reality is that therapeutic trials with corticosteroids, aspirin, antimicrobial agents may be considered\n\nMay delay correct diagnosis/treatment\nThe road to diagnosis of FUO is, by definition, long and frustrating\nClinicians are often pressured to treat symptoms"
  },
  {
    "objectID": "FUO.html#treatment-is-nearly-always-indicated",
    "href": "FUO.html#treatment-is-nearly-always-indicated",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Treatment is nearly always indicated",
    "text": "Treatment is nearly always indicated\n\n\nEmpirical treatment with corticosteroids in patients with suspected temporal arteritis to prevent vascular complications such as blindness and stroke\nFebrile neutropenia: high prevalence of serious bacterial infections- patients should receive broad-spectrum antimicrobial therapy with anti-pseudomonas coverage after appropriate cultures are obtained\nTherapeutic trials with narrow spectrum therapy (e.g. anti-mycobacterial agents) may be considered in select cases with history suggestive of TB"
  },
  {
    "objectID": "FUO.html#prognosis",
    "href": "FUO.html#prognosis",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Prognosis",
    "text": "Prognosis\n\n\nDetermined y the cause of fever and nature of underlying disease(s)\nElderly patients with malignant neoplasms have the poorest prognosis\nDiagnostic delay associated with poorer prognosis in:\n\nIntra-abdominal infections\nMiliary tuberculosis\nDisseminated fungal infections\nRecurrent pulmonary emboli\n\nPatients with undiagnosed FUO after extensive evaluation still generally have a a favourable outcome, with most patients experiencing resolution of fever within 4 weeks without sequlae.\n\n5-year mortality rates of 3%"
  },
  {
    "objectID": "FUO.html#references",
    "href": "FUO.html#references",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "References",
    "text": "References\n\n\n\n\n\n\nCorey L, Boeckh M. Persistent fever in patients with neutropenia. The New England Journal of Medicine 2002;346:222–4. https://doi.org/10.1056/NEJM200201243460402.\n\n\nde Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. Prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine 1997;76:392–400. https://doi.org/10.1097/00005792-199711000-00002.\n\n\nGabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. The New England Journal of Medicine 1999;340:448–54. https://doi.org/10.1056/NEJM199902113400607.\n\n\nHaidar G, Singh N. Fever of Unknown Origin. New England Journal of Medicine 2022;386:463–77. https://doi.org/10.1056/NEJMra2111003.\n\n\nKouijzer IJE, Mulders-Manders CM, Bleeker-Rovers CP, Oyen WJG. Fever of Unknown Origin: The Value of FDG-PET/CT. Seminars in Nuclear Medicine 2018;48:100–7. https://doi.org/10.1053/j.semnuclmed.2017.11.004.\n\n\nMackowiak PA, Bartlett JG, Borden EC, Goldblum SE, Hasday JD, Munford RS, et al. Concepts of Fever: Recent Advances and Lingering Dogma. Clinical Infectious Diseases 1997;25:119–38.\n\n\nMackowiak PA, Worden G. Carl Reinhold August Wunderlich and the evolution of clinical thermometry. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1994;18:458–67. https://doi.org/10.1093/clinids/18.3.458.\n\n\nPlayfair, J., Bancroft, G. Infection and Immunity, 4th Edition. Oxford University Press; 2013.\n\n\nSajadi, Mohammad M., Mackowiak, Philip A. Temperature Regulation and the Pathogenesis of Fever. Principles and Practice of Infectious Diseases, 8th Edition, Elsevier Health Sciences; n.d., p. 4739–452.\n\n\nSajadi, Mohammad M., Mackowiak, Philip A. Temperature Regulation and the Pathogenesis of Fever. Principles and Practice of Infectious Diseases, 8th Edition, London: Elsevier Health Sciences; 2015, p. 4739–520.\n\n\nSickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Archives of Internal Medicine 1975;135:715–9.\n\n\nWright WF, Auwaerter PG, Dibble EH, Rowe SP, Mackowiak PA. Imaging a Fever-Redefining the Role of 2-deoxy-2-[18F]Fluoro-D-Glucose-Positron Emission Tomography/Computed Tomography in Fever of Unknown Origin Investigations. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2021;72:1279–86. https://doi.org/10.1093/cid/ciaa1220.\n\n\nWright, William F., Mackowiak, Philip A. Principles and Practice of Infectious Diseases, 8th Edition. Fever of Unknown Origin, Elsevier Health Sciences; 2015."
  },
  {
    "objectID": "Index.html#welcome",
    "href": "Index.html#welcome",
    "title": "ME2491 Infectious Diseases",
    "section": "Welcome",
    "text": "Welcome\nWelcome to the ME2491 Medicine and Surgery INFECTIOUS DISEASES educational resources page.\nUsing the navigation bar on the right, you can find links to reading, educational websites, podcasts, and online antibiotic dosing models that will be of interest as you progress through the course.\nCore course materials will also be posted on the University Moodle Course site when activated."
  },
  {
    "objectID": "Resistance.html",
    "href": "Resistance.html",
    "title": "Antimicrobial Resitance in ESCAPE Pathogens",
    "section": "",
    "text": "A PDF copy of lecture slides can be downloaded here"
  },
  {
    "objectID": "Resistance.html#background-reading",
    "href": "Resistance.html#background-reading",
    "title": "Antimicrobial Resitance in ESCAPE Pathogens",
    "section": "Background reading",
    "text": "Background reading\nRecent comprehensive review of antimicrobial resistance in ESKAPE pathogens ESKAPE review\nInfectious Diseases Society of America Guidelines for Treating ESBL, CRE and Pseudomonas IDSA1\nInfectious Diseases Society of America Guidelines for Treating AMP-C beta-lactamases, Carbapenem-resistant Acinetobacter spp. and Stenotrophomonas IDSA2\nESCMID Guidelines for treatment of MDR Gram-Negative Organisms ESCMID\nExcellent review on AMP-C resistance AMP-C\nExcellent review on role of new antibiotics for carbapenem-resistant pathogens new agents"
  },
  {
    "objectID": "Allergies.html",
    "href": "Allergies.html",
    "title": "Antibiotic allergies",
    "section": "",
    "text": "Lecture slides can be downloaded here\nEssential review on diagnosing and managing penicillin allergies\nThe following links below may require access via University proxy. Click on the the “multimedia” link to find the videos and podcasts.\nJAMA Educational Videos and Podcasts on Evaulating, Manging and Testing Penicillin Allergies\nWhat every new doctor should know about adverse drug reactions\nExcellent and entertaining dicussion on PCN de-labeling\nPatient information on PCN allergy testing\nAmoxicillin challenge forms"
  },
  {
    "objectID": "Antibiotic.html",
    "href": "Antibiotic.html",
    "title": "Principles of Antibiotic Therapy",
    "section": "",
    "text": "A PDF copy of lecture slides can be downloaded here"
  },
  {
    "objectID": "Antibiotic.html#background-reading",
    "href": "Antibiotic.html#background-reading",
    "title": "Principles of Antibiotic Therapy",
    "section": "Background reading",
    "text": "Background reading\nAlthough published in 2011, this paper remains the highest-cited general review on Principles of Antibiotic Treatment\nClassic Antibiotic PK/PD Review\nSome information out of date, but this is a Classic Antibiotic PK/PD Review from the “father” of the field, Dr. William Craig, M.D.\nPK/PD and TDM Position Paper\nRecent review on antimicrobial susceptibiltiy testing methods\nIDSA Clinical Microbiology Guidelines 2018\nEUCAST Website"
  },
  {
    "objectID": "Antibiotic.html#links-to-prof.-sebastian-wichas-online-precision-antibiotic-dosing-models",
    "href": "Antibiotic.html#links-to-prof.-sebastian-wichas-online-precision-antibiotic-dosing-models",
    "title": "Principles of Antibiotic Therapy",
    "section": "Links to Prof. Sebastian Wicha’s online precision antibiotic dosing models",
    "text": "Links to Prof. Sebastian Wicha’s online precision antibiotic dosing models\nClick on this link: TDMx\n Note: The UNIPD Proxy may block the TDMx landing page for the models, but individual drug model pages demonstrated in class still seemed to be accessible through the proxy:\nGentamicin  Vancomycin  Meropenem"
  },
  {
    "objectID": "FUO.html#bone-marrow-biopsy",
    "href": "FUO.html#bone-marrow-biopsy",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Bone marrow biopsy",
    "text": "Bone marrow biopsy\n\n\nGranulomatous infections (e.g., tuberculosis, histoplasmosis, sarcoidosis)\nPatients with abnormal complete blood counts (CBC)"
  },
  {
    "objectID": "immunosuppression.html#infections-in-the-immunocompromised-host",
    "href": "immunosuppression.html#infections-in-the-immunocompromised-host",
    "title": "Infections in the Immunocompromised Host",
    "section": "Infections in the Immunocompromised Host",
    "text": "Infections in the Immunocompromised Host\n\n\nRussell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  13 March 2023"
  },
  {
    "objectID": "immunosuppression.html#objectives",
    "href": "immunosuppression.html#objectives",
    "title": "Infections in the Immunocompromised Host",
    "section": "Objectives",
    "text": "Objectives\n\nReview common immunosuppression risk factors for infection in patients undergoing treatment for cancer/hematological malignancies\nAnticipate most likely infections based on the the types of immunosuppression\nDefine appropriate prophylaxis and treatment strategies for immunocompromised hosts"
  },
  {
    "objectID": "immunosuppression.html#healthy-host",
    "href": "immunosuppression.html#healthy-host",
    "title": "Infections in the Immunocompromised Host",
    "section": "Healthy host",
    "text": "Healthy host\n\n\nProtection against most pathogens through complex and redundant network of:\n\nProtective surfaces\nCells (e.g., granulocytes, macrophages, NK cells)\nSoluble factors (antibody, complement)\nResident microbiota (competition for binding sites and available nutrients as well as shaping the immune system)"
  },
  {
    "objectID": "immunosuppression.html#references",
    "href": "immunosuppression.html#references",
    "title": "Infections in the Immunocompromised Host",
    "section": "References",
    "text": "References\n\n\n\n\n\n\nBodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966;64:328–40."
  },
  {
    "objectID": "immunosuppression.html#innate-immune-system",
    "href": "immunosuppression.html#innate-immune-system",
    "title": "Infections in the Immunocompromised Host",
    "section": "Innate immune system",
    "text": "Innate immune system\n\n\nArchitha Srinivasan, Cambridge University"
  },
  {
    "objectID": "immunosuppression.html#immunosuppressed-host",
    "href": "immunosuppression.html#immunosuppressed-host",
    "title": "Infections in the Immunocompromised Host",
    "section": "Immunosuppressed host",
    "text": "Immunosuppressed host"
  },
  {
    "objectID": "immunosuppression.html#deficiencies-in-host-defences",
    "href": "immunosuppression.html#deficiencies-in-host-defences",
    "title": "Infections in the Immunocompromised Host",
    "section": "Deficiencies in host defences",
    "text": "Deficiencies in host defences\n\n\nAlthough certain organisms can infect patients with specific immune defects, it is not always predictable\nBasic patterns are recognizable, but the types and severity of complications is often unpredictable\n\nSingle, isolated deficiencies are the exception rather than the rule\nMultiple defence mechanisms are often affected\n\ne.g., chemotherapy → mucosal barrier injury + neutropenia\ne.g., stem cell transplantation → chemotherapy → immunosuppressive therapy + delayed reconstitution of adaptive immunity + graft versus host disease (GVHD)"
  },
  {
    "objectID": "immunosuppression.html#granulocytopenia",
    "href": "immunosuppression.html#granulocytopenia",
    "title": "Infections in the Immunocompromised Host",
    "section": "Granulocytopenia",
    "text": "Granulocytopenia\n\nInfection rateFatality rate\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(Bodey et al., 1966)"
  }
]